SEC Form 3 · accession 0001209191-18-052346
SUTRO BIOPHARMA, INC. · STRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph M Lobacki
Director
Period of report
Sep 26, 2018
Accepted (ET)
Sep 26, 2018 · 6:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001382101
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| No securities beneficially held | holding | — | — | — | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy Common Stock)F1 | $13.07 | holding | — | — | — | — | Dec 5, 2027 | Common Stock | 16,345 | — | D |
Explanation of responses
- F1The option vests as to 4.167% of the total shares monthly, beginning on March 6, 2017, with 100% of the total shares vested and exercisable on February 6, 2019, subject to the reporting person's provision of service to the issuer on each vesting date.